[Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <em>in vitro</em>

Kroschwald,Lysann Michaela; Tauer,Josephine Tabea; Kroschwald,Sonja Ingrid; Suttorp,Meinolf; Wiedenfeld,Anne; Beissert,Stefan; Bauer,Andrea; Rauner,Martina

doi:10.3892/ol.2026.15688

August-2026 Volume 32 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2026 Volume 32 Issue 2

Full Size Image

Correction Open Access

[Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro

Authors:
- Lysann Michaela Kroschwald
- Josephine Tabea Tauer
- Sonja Ingrid Kroschwald
- Meinolf Suttorp
- Anne Wiedenfeld
- Stefan Beissert
- Andrea Bauer
- Martina Rauner
View Affiliations / Copyright

Affiliations: Department of Dermatology, Medical Faculty, D-01307 Dresden, Germany, Department of Pediatrics, Shriners Hospital for Children, McGill University, Montreal QC H4A 0A9, Canada, Simon Alberti Group, Max Planck Institute of Molecular Cell Biology and Genetics, D-01307 Dresden, Germany, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Medical Faculty, D-01307 Dresden, Germany, Department of Medicine III and Center for Healthy Aging, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany

Copyright: © Kroschwald et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 333
|
Published online on: June 10, 2026

https://doi.org/10.3892/ol.2026.15688
Expand metrics +

Article

Oncol Lett 18: [Related article:] 2102–2108, 2019; DOI: 10.3892/ol.2019.10518

Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that, regarding the experiments showing the synthesis of mineralized bone matrix in the osteoblast-like cell line SaOS-2 in Fig. 1 on p. 2104, the ‘Day 10/Control’ and ‘Day 15/IAM’ data panels were apparently matching, suggesting that the data in this figure had been assembled incorrectly.

Figure 1.

Synthesis of mineralized bone matrix in the osteoblastic-like cell line SaOS-2 under treatment with IMA (middle column, 1 µM) and NIL (1 µM, right-hand column) in comparison with untreated control (left-hand column): Hemofix-stained samples at different time points (day 0, 5, 10, 15 or 25) of incubation. Mineralized areas are represented by black areas. Representative pictures are shown (n=3). IMA, imatinib; NIL, nilotinib.

The authors have realized that the ‘Day 10/Control’ data panel was inadvertently copied across to show the results of the ‘Day 15/IAM’ experiment. The revised version of Fig. 1, now showing the correct data panel for the ‘Day 15/IAM’ experiment, is shown on the next page. The authors regret the error that were made while compiling the original figure, and are grateful to the editor of Oncology Letters for allowing them the opportunity to publish this Corrigendum. Note that this error did not have a significant impact on the conclusions reported in this study. All the authors agree with the publication of this corrigendum; furthermore, they apologize to the readership for any inconvenience caused.